


## Pioneering Therapeutic Nanocatalysts That Improve Cellular Bioenergetics

Clene Inc. (NASDAQ: CLNN) is a clinical stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative disease. Clene’s lead drug candidate, CNM-Au8, a suspension of pure gold nanocrystals, has shown promising efficacy in improving neurological function in multiple preclinical studies<sup>1</sup>.

### Anticipated Timeline & Investor Catalysts 2020-2023



**CNM-Au8** is under investigation in multiple clinical trials for disease modification in the treatment of neurodegenerative disease including a Phase 3 registration trial and Phase 2 in ALS (HEALEY-ALS Platform) and (RESCUE-ALS), a Phase 2 study in MS (VISIONARY-MS) for the treatment of stable relapsing multiple sclerosis, and Phase 2 target engagement studies in Parkinson’s disease and MS (REPAIR-PD) and (REPAIR-MS).

Clene is leading the way by using nanotechnology to treat bioenergetic failure, which underlies many neurological diseases, Clene is delivering the potential for neuroreparative treatment. The Phase 3 registrational platform trial (HEALEY-ALS), if successful, could lead to approval and commercialization in 2023.

### CNM-Au8 | Significant Global Opportunity



#### MOTOR NEURON DISEASE (ALS, Other Orphan Disorders)

ALS sales >\$1B globally by 2029.<sup>2</sup> Current drugs are largely ineffective, mostly generic.



#### MULTIPLE SCLEROSIS

~2.5M pts globally; \$23B market<sup>3</sup>  
Only approved treatments are immunomodulators



#### PARKINSON'S DISEASE

~7M pts globally; \$6B projected by 2025<sup>4</sup>  
2nd most common neurodegenerative disorder; only symptomatic treatment

### Forward Looking Statements:

This document contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Clene’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant known and unknown risks and uncertainties, many of which are beyond Clene’s control and could cause actual results to differ materially and adversely from expected results. Factors that may cause such differences include Clene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; Clene’s ability to achieve commercial success for its marketed products and drug candidates, if approved; Clene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Clene’s reliance on third

parties to conduct drug development, manufacturing and other services; Clene’s limited operating history and its ability to obtain additional funding for operations and to complete the licensing or development and commercialization of its drug candidates; the impact of the COVID-19 pandemic on Clene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled "Risk Factors" in Clene’s recently filed registration statement on Form S-4, as well as discussions of potential risks, uncertainties, and other important factors in Clene’s subsequent filings with the U.S. Securities and Exchange Commission. Clene undertakes no obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

#### References Cited

1. Robinson et al. Sci Rep. 2020 Feb 11;10(1):1936.
2. Clarivate, DRG, ALS 2020.
3. Westad et al. 2017, doi:10.1038/nrd.2017.107.
4. Parkinson’s Market Data Forecast, February 2020.